3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-06), Barinthus Biotherapeutics's 3-1 Month Momentum % is 21.77%.
The industry rank for Barinthus Biotherapeutics's 3-1 Month Momentum % or its related term are showing as below:
STU:2AB's 3-1 Month Momentum % is ranked better than 76.89% of 1376
companies
in the Biotechnology industry
Industry Median: -7.23
vs STU:2AB: 21.77
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Barinthus Biotherapeutics 3-1 Month Momentum % Related Terms
STU:2AB vs VTGN, PSTV, PVCT: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a 3-1 Month Momentum % of 21.77% as of Jul. 06, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #318 out of 1376 companies in the Biotechnology industry, placing it in the top 23.1%.
Is Barinthus Biotherapeutics' 3-1 Month Momentum % too high?
Barinthus Biotherapeutics' current 3-1 Month Momentum % is 21.77%. Based on the distribution chart, Barinthus Biotherapeutics ranks #318 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' 3-1 Month Momentum % compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #318 out of 1376 companies for 3-1 Month Momentum %. This places Barinthus Biotherapeutics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current 3-1 Month Momentum % is 21.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current 3-1 Month Momentum % of 21.77%. The stock's GF Value™ is €0.94, compared to a current price of €0.52 — trading 44.7% below its estimated fair value. The current 3-1 Month Momentum % is 21.77%. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current 3-1 Month Momentum % is 21.77% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.52 is trading 44.7% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
3-1 Month Momentum %: 21.77%
GF Value™: €0.94 vs. price of €0.52 (44.7% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 